THE TRADENS

PTO/58/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		U.S. Petent and Trademark Office; U.S. DEPARTMENT OF C rsons are required to respond to a collection of information unless it contains a valid OMB contraction of the			
				Application Number	10/810,517
	INFORMATION DISCLOSURE			Filing Date	March 26, 2004
STA	ATEME	NT BY	APPLICANT s as necessary)	First Named Inventor	Kreft et al.
	(030 83 11	iany sneet	s as necessary)	Group Art Unit	1626
			·	Examiner Name	unassigned 1626
Sheet	1	of	6	Attorney Docket Number	AM-101251

	U.S. PATENT DOCUMENTS								
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where				
Initials*	No.1	Number-Kind Code ((trace)	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear				
GS	AA	US-5,981,168	P. Reiner	11-09-1999					
	AB	US-5,624,937	J. Reel	04-29-1997					
	AC	US-5,703,129	K. Felsenstein	12-30-1997					
	AD	US-5,593,846	D. Schenk	01-14-1997					
	AE	US-5,852,007	S. Chatterjee	12-22-1998					
·	AF	US-6,248,775	Vasquez	06-19-2001					
	AG	US-6,376,523	Chan, et al.	04-23-2002					
Ψ	AH	US-5,594,021	Chan, et al.	01-14-1997	Claims 1 and 2, and Specification				

· · · · · · · · · · · · · · · · · · ·		FOREIG	ON PATENT DOCUME	NTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	70
Initials*	No.1	Country Code ³ - Number ⁴ -Kind Code ⁵ (# known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures	
GS	AL	WO-95/29904-A1	11-09-1995	K. Chow	Appear	┼
	AM	WO-98/03166-A1	01-29-1998	G. DeCrescenzo		┼-
	AN	WO-98/22104-A3	05-28-1998	G. Pasinetti		╄
	AO	WO-98/22493-A2	05-28-1998	J. Audia		
	AP	WO-00/09107-A2	02-24-2000	D. Ross		1
Ψ	AQ	WO-00/50391-A1	08-31-2000	D. Ross D. Smith		╂—

Examiner				
Signature	/Golam Shameem/	(09/14/2006)	Date	00/14/0006
* FYAMATACO	<u> </u>		Considered	09/14/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
collection of information unless it contains a valid OMB Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

Substitut	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/810,517	
			DISCLOSURE	Filing Date	March 26, 2004	
			APPLICANT	First Named Inventor	Kreft et al.	
	(USC BS III	iarry streets	as necessary)	Group Art Unit	1626	
				Examiner Name	unassigned	
Sheet	2	of	6	Attorney Docket Number	AM-101251	

		· · · · · · · · · · · · · · · · · · ·	U.S. PATENT DOCUM	ENTS .	
Examiner Cite		Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where
Initials* No.1	No.1	Number-Kind Code ^{2(if trees)}	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
GS	AI	US-5,571,821	Chan, et al.	11-05-1996	
	AJ	US-5,464,853	Chan, et al.	01-07-1997	
	AK	US-5,591,761	Chan, et al.	05-07-1996	
V	BA	US-5,514,691	Chan, et al.	11-07-1995	

•		·		FOREIGN PATENT	DOCUMENTS		
_	Examiner Cite 'Initials* No.1		Foreign Patent Document			Pages, Columns,	
			Country Code ³ - Number ⁴ -Kind Code ³ (II known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Lines, Where Relevant Passages or Relevant Figures	14
	GS	BL	EP-652,009	05-10-1995	V. John	Appear	
		BM	EP-510,700-A2	10-28-1992	K. Itoh et al.		-
		BN	EP-1,172,361-A1	12-14-1999	Watanabe et al.	 	
		BO	JP-5-148233	06-15-1993	Y. Ito	-	1
		BP	JP-11-343279	01-16-2002	F. Watanabe	 	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
		BQ	WO-01/27091-A1	04-19-2001	Thompson	 	 -
		CL	WO-01/27108-A1	04-19-2001	Thompson		
٦	1	CM	WO-01/23379-A1	04-05-2001	Arkinstall et al.		⊢-
		CN	EP-1,088,821-A1	04-04-2001	Arkinstall		

Examiner				_
	/Golam Shameem/ (09/	14/2006)	Date	
Signature			Considered	09/14/2006
* EXAMINER: Init!	al if reference considered, whether or not allegate		Considered	03/14/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitut	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/810,517	
INFORMATION DISCLOSURE				Filing Date	March 26, 2004	
	STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Kreft et al.		
	(USE as n	nany sneets	s as necessary)	Group Art Unit	1626	
				Examiner Name	unassigned	
Sheet	3	of	6	Attorney Docket Number	AM-101251	

			U.S. PATENT DOCUM	ENTS	
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Where
	No.1	Number-Kind Code ^{2(if known)}	MM-DD-YYYY	or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
GS L	·BB	US-6,657,070	12-02-2003	Resnick, et al.	
	BC	US-6,610,734	08-26-2003	Kreft, et al.	
	BD	US-20030229127-A1	12-11-2003	Kreft, et al.	
	BE	US-20030144531-A1	07-31-2003	Kreft, et al.	
	BF	US-20040006050-A1	01-08-2004	Kreft, et al.	
\mathbf{V}_{-}	BG	6,566,536	05-20-2003	Muller, et al.	

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ -Kind Code ⁵ (II known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	T ⁶				
GS	СО	WO-01/70677-A1	09-27-2001	Belanger et al.	Appear	_				
	CP	WO-02/057252-A1	07-25-2002	Kreft et al.		_				
	CQ	WO-03/050063-A1	06-19-2003	Kreft et al.						
	DL	WO-03/103660-A1	12-18-2003	Kreft et al.						
Ψ_{-}	DM	WO-03/050062-A1	06-19-2003	Resnick et al.		-				
						 				

Examiner	19 3 9	100/0/100		
Signature	/Golam Shameem/	(09/14/2006)	Date	09/14/2006
* SYAMINED. 1-14	<u> </u>		Considered	03/14/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ¹See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

6

Sheet

10/810,517 Filing Date March 26, 2004 First Named Inventor Kreft et al. Group Art Unit 1626 **Examiner Name** unassigned **Attorney Docket Number** AM-101251

•		NONPATENT LITERATURE DOCUMENTS				
Examiner . Initials*			T ²			
GS	AR	A. LARNER et al, "Review - Central & Peripheral Nervous Systems - Alzheimer's				
i		Disease: Towards Therapeutic Manipulation of the Amyloid Precursor Protein and	ŀ			
		Amyloid p-peptides", Exp. Opin. Ther. Patents 7(10) 1115-1127 (1007)				
	AS	C. MOORE et al, "Inhibition of β-amyloid Formation as a Therapeutic Strategy", Exp.	┼			
		Copin. Ther. Patents, 9(2):135-146 (1999)				
	AT	V. JOHN et al, "Alzheimer's Disease: Recent Advances on the Amyloid Hymothesis"	+			
		In Admusi Reports in Medicinal Chemistry Chapter 2 pp. 11-20 (1907)	İ			
	AU	U. RISHIUN et al. "Fenchylamine Sulfonamide Inhibitors of Amyloid & Dordida				
		Production by the γ-Secretase Proteolytic Pathway: Potential Small-Molecule				
		Therapeutic Agents for the Treatment of Alzheimer's Disease", J. Med. Chem.,				
		43(12):2297-2299 (June 15, 2000)				
	AV	B. TESTA et al, "Prodrugs Revisited: The "Ad Hoc" Approach as a Complement to	 			
		Ligand Design, Medicinal Research Reviews 16(3):233-241 (May 1006)				
	AW	D. SKOVRONSKY et al, "β-Secretase Revealed: Starting Gate for Race to Novel	 			
		inerapies for Alzheimer's Disease", TIPS, 21:161-163 (May, 2000)				
	AX	A. GHOSH et al, "Design of Potent Inhibitors for Human Brain Memansin 2 (8)	 			
		Secretase), J. Am. Chem. Soc., 122:3522-3523 (2000)				
	AY	W. ESLER et al, "Transition-State Analogue Inhibitors of v-Secretage Bind Discotly As	┽			
		riesemin-1, Nature Cell Biology, 2:428-434 (July 2000)				
	AZ	Y-M. LI et al, "Photoactivated y-Secretase Inhibitors Directed to the Active Site	 			
\		Covalently Label Presentlin 1", Nature, 405:689-694 (June, 2000)				
V	BR	M. WOLFE et al, "A Substrate-Based Diffuoro Ketone Selectively Inhibite	+			
		Alzheimer's β-Secretase Activity", J. Med. Chem., 41:6-9 (January 1, 1998)				

Examiner				
Signature	/Golam Shameem/	(09/14/2006)	Date	09/14/2006
	7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 - 7 -	(0.5/22/2000)	Considered	1 03/ ==/ ==000

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/810,517 INFORMATION DISCLOSURE Filing Date March 26, 2004 STATEMENT BY APPLICANT First Named Inventor Kreft et al. Group Art Unit 1626 (Use as many sheets as necessary) **Examiner Name** unassigned of 6 Attorney Docket Number

AM-101251

Sheet

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	e T2
GS BS		S. SINHA et al, "Purification and Cloning of Amyloid Precursor Protein β-Secretase from Human Brain", Nature, 402:537-540 (December, 1999)	-
	ВТ	A. GOATE, "Monogenetic Determinants of Alzheimer's Disease: APP Mutations", CMLS Cell. Mol. Life Sci., 54:897-901 (September, 1998)	
	BU	M. SABBAGH et al, "β-Amyloid and Treatment Opportunities for Alzheimer's Disease", Alzheimer's Disease Review, 3:1-19 (1997)	
•	BV	C. AUGELLI-SZAFRAN et al, "β-Amyloid as a Target for Alzheimer's Disease Therapy, in Annual Reports in Medicinal Chemistry, Chapter 3, pp. 21-30 (1999)	
•	BW	Biology to Learning and Memory Processes", Reviews in the Neurosciences, 11(2-3):75-93 (2000)	
	BX	D. SMALL et al, "Alzheimer's Disease and the Amyloid β Protein: What is the Role of Amyloid?", Journal of Neurochemistry, 73(2):443-449 (August, 1999)	
	BY	J. NÄSLUND et al, "Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline", JAMA, 283(12):1571-1577 (March, 2000)	
	BZ	Q-X. LI et al, "The Amyloid Precursor Protein of Alzheimer Disease in Human Brain and Blood", Journal of Leukocyte Biology, 66:567-574 (October, 1999)	
	CR	S. WAGNER et al, "Modulation of Amyloid \(\beta\) Protein Precursor Processing as a Means of Retarding Progression of Alzheimer's Disease", The Journal of Clinical Investigation, 104(10):1329-1332 (November, 1999)	
	CS	Y. HAN et al, "Total Asymmetric Synthesis of Highly Constrained Amino Acids Isopropyl-2', 6'-Dimethyl-Tyrosines" Tetrahedron Letters, 38(20):5135-5138 (1007)	
V	CT	M. FINDEIS et al, "Modified-Peptide Inhibitors of Amyloid β-Peptide Polymerization", Biochemistry, 38(21):6791-6800 (May, 1999)	

Examiner			
Examiner	/0-1 01/ /00/5	1 (0000)	
Signature	Golam Shameem/ (09/1	4/2()()6) Date	
Organitate	/ 00-00. 21-00-00-00./ (03/2	11/2000/	1 00/14/2006
		Considered	09/14/2006

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to Complete if Known Substitute for form 1449/PTO **Application Number** 10/810.517 **INFORMATION DISCLOSURE** Filing Date March 26, 2004 STATEMENT BY APPLICANT First Named Inventor Kreft et al. Group Art Unit 1626 (Use as many sheets as necessary) **Examiner Name** unassigned Sheet 6 of 6 Attorney Docket Number AM-101251

		NONPATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GS ——	CU	ROGGO, "Inhibition of BACE, A Promising Approach to Alzheimer's Disease Therapy", Curr. Top. Med. Chem., 2(4): 359-70 (April 2002)	
	CV	TUNG et al., "Design of Substrate-Based Inhibitors of Human β-Secretase", J. Med. Chem., 45(2):259-262 (2002)	
	CW	JOSIEN, "Recent Advances in the Development of Gamma-Secretase Inhibitors", Curr. Opin. Drug. Discov. Devel., 5(4):513-25 (July 2002)	
	CX	DOVEY et al., "Functional Gamma-Secretase Inhibitors Reduce Beta-Amyloid Peptide Levels in Brain", J. Neurochem., 76:173-181 (January 2001)	
•	CY	OLSON et al., "Chapter 4. Secretase Inhibitors as Therapeutics for Alzheimer's Disease", Ann. Reports in Med. Chem., 35:31 (2000)	
	CZ	VARGHESE et al., "Chapter 2. Alzheimer's Disease: Recent Advances on the Amyloid Hypothesis", Ann. Reports Med. Chem., 32:11 (1997)	
V	DL	Abstract of Japanese Patent No. JP-11-343279, January 26, 2002	

Signature /Golam S	nameem/ (09/14/2006)		
Signature / GOTam 5	Tameem/ (03/14/2000)	Date	00/44/2004
Orgretate			09/14/2006
		Considered	1 05/14/2000

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent Patents, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1949/110				Complete if Known		
				Application Number	10/810,517	
INF	ORMATION	DIS	CLOSURE	Filing Date	March 26, 2004	
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Kreft et al.	
(Use as many sheets as necessary)				Art Unit	1626	
				Examiner Name	u nassigned. 1626	
Sheet	1	of	1	Attorney Docket Number	AM-101251	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GS	DM	WERMUTH et al., "Molecular variations based on isosteric replacements", Prac. Med. Chem., Academic Press, pp. 203-237 (February 1996)	
· · ·			
		·	
- · · · -			
		·	

Examiner Signature	/Golam Shameem/	(09/14/2006)	Date Considered	09/14/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.